BIOMAT Database Logo BIOMAT Database Logo

Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells. 2017

Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
Department of Coloproctology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University.

Activation of the signal transducer and activator of transcription 3 (STAT3) is observed in multiple cancer types, including gastric cancer, and represents a potential drug target for chemotherapy. Currently, clinically available small-molecule inhibitors targeting STAT3 are lacking. Here, we report that nifuratel, an antiprotozoal and antifungal drug, is a potent inhibitor of STAT3. We found that nifuratel significantly suppressed proliferation and induced apoptosis of gastric cancer cells. Studies of the mechanism of action of nifuratel indicated that it acts by inhibiting the constitutive and interleukin-6-induced STAT3 activation. Taken together, our findings demonstrate that nifuratel may be a novel, clinically accessible STAT3 inhibitor in gastric cancer cells.

UI MeSH Term Description Entries

Related Publications

Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment.
October 2022, Journal of medicinal chemistry,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cells.
August 2023, Natural products and bioprospecting,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
April 2012, International journal of oncology,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.
March 2015, Oncogene,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma.
January 2019, American journal of cancer research,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro.
November 2009, Cancer letters,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation.
May 2011, International journal of oncology,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
Novel FtsZ inhibitor with potent activity against Staphylococcus aureus.
October 2021, The Journal of antimicrobial chemotherapy,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells.
December 2016, The Prostate,
Hailun Zheng, and Huang Hong, and Lulu Zhang, and Xiong Cai, and Meng Hu, and Yuepiao Cai, and Bin Zhou, and Jiayuh Lin, and Chengguang Zhao, and Wanle Hu
HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.
October 2008, Anti-cancer drugs,
Copied contents to your clipboard!